San Pedro, CA – September 18, 2007
1. Two substances that induce cell death in pleural mesothelioma are promising candidates for local treatment within multimodality treatment plans. Link here.
2. Anti-mesothelin immunotoxin shows promise and is slated for Phase II clinical trial for mesothelioma patients. Link here.
3. Using thoracoscopy under local anesthesia rather than general anesthesia is recommended as a diagnostic procedure for cases with pleural diseases. Link here.
4. The export of Canadian asbestos to developing countries sets the stage for another preventable occupational disease epidemic that will manifest over the coming decades. Link here.
5. Mesothelioma increasing in Australia, along with the mean latency and number of “non-occupational” cases. Link here.
6. Radiotherapy and intraperitoneal paclitaxel suitable in palliative settings to improve the quality of life in advanced peritoneal mesothelioma. Link here.
7. Phase II testing of sunitinib, an inhibitor that affects tumour proliferation and angiogenesis in cancers including mesothelioma. Link here.
8. Disrupting angiogenesis mediated by malignant mesothelioma cells. Link here.
9. Possible chemotherapy role for activated and latent signal transducer and activator of transcription 3 in mesothelioma cases. Link here.
10. Phase II trials planned for recombinant anti-mesothelin immunotoxin for malignant mesothelioma patients. Link here.
11. Serum mesothelin is a promising marker for the diagnosis, prognosis, and clinical monitoring of malignant mesothelioma. Link here.
12. Multivitamin/mineral supplement use and its effect on cancer prevention. Link here.
13. Pericardial mesothelioma patient with metastases to liver responds well to pemetrexed and carboplatin-based combination chemotherapy. Link here.
14. Combination of radiotherapy and intraperitoneal paclitaxel suitable in palliative settings aimed at improving the quality of life. Link here.
15. Flow cytometric immunophenotyping is an effective method for characterizing cancer cells in clinical effusion specimens and is comparable to immunohistochemistry in terms of sensitivity and specificity. Link here.
16. Intraoperative chemotherapy with heat benefits patients with peritoneal and pleural mesothelioma. Link here.